Related Experiment Videos
Monoclonal antibody-porphyrin conjugate for head and neck cancer: the possible magic bullet
P J Donald1, R D Cardiff, D E He
1Department of Otolaryngology-Head and Neck Surgery, University of California, Davis.
Abstract:
Although photodynamic therapy in the treatment of large head and neck cancers showed some initial promise, the results in the final analysis have been somewhat disappointing. Lack of specificity and nonhomogeneous uptake of the porphyrin by the tumor are only some of the problems. The conjugation of a monoclonal antibody (UCD/AB 6.01) with hematoporphyrin derivative that preferentially binds to tumor cells offers promise as a therapeutic agent that will not only improve specificity, but vastly enhances tumor cell kill when exposed to light in its photodynamic range. The application of the monoclonal antibody-hematoporphyrin conjugate (AB:HPD) to A-431 squamous cell carcinoma cells in vitro, followed by exposure to light in the 630 nm range, increases the kill ratio by a factor of 10(5) times. The active tumor cell binding site on the cell surface has been found to be on the microvilli, a site at which a 52 kDa protein that is very similar to keratin 8 is found. The clearance of the conjugate from nude mice who have grown an A-431 tumor shows a retention of AB:HPD of approximately 15% and less than 1% in skin and internal organs when measured at 48 hours. Direct application of AB:HPD to fresh pathology specimens containing human squamous cell carcinomas shows binding exclusively limited to the tumor.
Insights
A novel antibody-hematoporphyrin conjugate (AB:HPD) significantly enhances photodynamic therapy for head and neck cancers. This targeted approach improves specificity and increases tumor cell kill by 100,000-fold.
Area of Science:
- Oncology
- Biotechnology
- Photochemistry
Background:
- Photodynamic therapy (PDT) for head and neck cancers has shown limited success due to poor specificity and uneven drug uptake.
- Hematoporphyrin derivative (HPD) is a photosensitizer used in PDT, but its tumor-targeting capabilities are suboptimal.
Purpose of the Study:
- To develop a targeted photosensitizer for enhanced photodynamic therapy of squamous cell carcinoma.
- To evaluate the efficacy and specificity of a monoclonal antibody-hematoporphyrin derivative conjugate (AB:HPD) in vitro and in vivo.
Main Methods:
- Conjugation of a monoclonal antibody (UCD/AB 6.01) with hematoporphyrin derivative (HPD).
- In vitro testing on A-431 squamous cell carcinoma cells, followed by light exposure (630 nm).
- In vivo studies in nude mice bearing A-431 tumors to assess conjugate clearance and biodistribution.
- Ex vivo analysis of fresh human squamous cell carcinoma pathology specimens.
Main Results:
- The AB:HPD conjugate demonstrated a 10^5-fold increase in tumor cell kill ratio in vitro compared to HPD alone.
- In nude mice, AB:HPD showed favorable pharmacokinetics with ~15% retention in tumors at 48 hours and minimal uptake (<1%) in healthy tissues.
- Ex vivo application confirmed exclusive binding of AB:HPD to tumor cells in human squamous cell carcinoma specimens.
- The binding site was identified on microvilli, associated with a 52 kDa protein similar to keratin 8.
Conclusions:
- The antibody-hematoporphyrin conjugate (AB:HPD) represents a promising targeted therapeutic agent for photodynamic therapy.
- AB:HPD significantly improves specificity and efficacy in treating squamous cell carcinoma.
- Targeted delivery via monoclonal antibody conjugation overcomes limitations of traditional photodynamic therapy.